New Alzheimer’s Drug Approved by FDA

Having an effective estate plan, or updating an existing plan, must be completed while you have the requisite capacity or the changes could be challenged. However, the appointment of a guardian may become necessary if there is no estate plan and your loved one is incapacitated and no longer able to manage his or her financial or healthcare decisions without assistance as a result of the effects of Alzheimer’s Disease.

Alzheimer’s disease is an irreversible, progressive brain disorder affecting more than 6.5 million Americans that slowly destroys memory and thinking skills and, eventually, the ability to carry out simple tasks. While the specific causes of Alzheimer’s are not fully known, it is characterized by changes in the brain. Signs of the disease include significant memory loss, poor judgement, loss of spontaneity, forgetfulness and repeating statements (known as “perseveration”). The risk of Alzheimer’s Disease increases with age and, generally, twice as many women develop Alzheimer’s compared to men.

The U.S. Food and Drug Administration recently granted approval of Leqembi™ for the treatment of early Alzheimer’s disease.  The drug was approved using the Accelerated Approval pathway, under which the FDA may approve drugs for serious conditions where there is an unmet medical need and a drug is shown to have an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients.

Can Alzheimer’s be prevented? Not yet. But according to medical authorities, healthy lifestyle choices, such as diet, exercise and not smoking, may play a role in reducing the risk of the disease.

This new drug has been proven in clinical trials to slow the progression of this neurodegenerative disease in its early stage. The approval is expected to trigger coverage by the Centers for Medicare and Medicaid Services. This will expand access to the drug for an estimated one million people diagnosed with early-stage disease.

Source:  https://www.psychiatrist.com/news/fda-approves-new-drug-for-early-alzheimers/

Drizin Law is providing this information for educational purposes only. It should not be construed as legal advice or a legal opinion as to any specific facts or circumstances. This information is based on general principles of Nevada law at the time it was created and you should be aware laws frequently change.

Moreover, the laws affecting you may differ depending on the circumstances. You should consult with a qualified attorney in your own state or jurisdiction concerning your particular situation. Review of this information does not create an attorney-client relationship.

Biography

Lee is an experienced Nevada Attorney. He focuses on probate, wills, trusts, guardianship and real estate for a wide range of clients.

Mr. Drizin been representing families for more than 30 years. He has represented families in all aspects of probate, trust and guardianship administration including, but not limited to, commencement of proceedings, will and trust contests, accountings, and sales of real estate.